Skip to main content
main-content

ASCO 2019

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

2019 ASCO Annual Meeting coverage

Breaking news and expert interviews from the meeting in Chicago (May 31–June 4), including reporting of the ENZAMET, TITAN, and RELAY trials.

Conference overview

The 2019 ASCO Annual Meeting (ASCO 2019) is the largest international oncology meeting and showcases the latest research and clinical guidance. Below we provide coverage of research presented in the areas of genitourinary and thoracic cancers.

Conference coverage

ASCO 2019 ended on Tuesday 4 June, you can see our coverage below.


Genitourinary cancers

Expert interviews

12-06-2019 | Urothelial cancer | ASCO 2019 | Article

Expert comment: Phase II trial of enfortumab vedotin in urothelial cancer

ASCO expert Robert Dreicer gives his quick take on why the enfortumab vedotin data reported at the meeting hold so much promise for advanced urothelial carcinoma patients who have progressed on prior therapy (1:25).

12-06-2019 | Urothelial cancer | ASCO 2019 | Article

Researcher comment: Enfortumab vedotin active in advanced urothelial carcinoma

Investigator Daniel Petrylak summarizes the key results of the phase II EV-201 trial of the antibody–drug conjugate enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer (2:42).

04-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Expert comment: ENZAMET and TITAN trials

Earle Burgess provides an independent commentary on the ENZAMET and TITAN results presented at the 2019 ASCO Annual Meeting, and discusses what these data mean for patients and physicians (2:57).

04-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Researcher comment: OS boost with enzalutamide in metastatic CSPC setting

Christopher Sweeney presents the main findings of the ENZAMET trial, which evaluated the impact of supplementing androgen deprivation therapy with enzalutamide in men with advanced castration-sensitive prostate cancer (3:10).

01-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Researcher comment: Apalutamide addition improves metastatic CSPC survival

Study author Axel Merseburger takes us through the TITAN trial investigating the addition of apalutamide to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting, and also addresses the key question of how physicians should choose between the available treatment options (3:03).

Research news

25-06-2019 | Renal cell carcinoma | ASCO 2019 | News

JAVELIN Renal 101 biomarker analysis may help personalize patient care

Biomarker analysis has given fresh insight into the response achieved with avelumab plus axitinib among advanced renal cell carcinoma patients participating in the JAVELIN Renal 101 trial.

21-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

Race-based difference in survival with sipuleucel-T therapy confirmed

Following treatment with the autologous cellular immunotherapy sipuleucel-T for metastatic castration-resistant prostate cancer, African–American men can expect to live longer than their Caucasian counterparts, indicates an analysis of the PROCEED registry.

18-06-2019 | Renal cell carcinoma | ASCO 2019 | News

Sarcomatoid RCC patients benefit from immune checkpoint inhibitor therapy

Subgroup analysis of the IMmotion151 trial suggests improved survival with first-line atezolizumab plus bevacizumab versus sunitinib for locally advanced or metastatic renal cell carcinoma patients with sarcomatoid differentiation.


Thoracic cancers

Expert interviews

19-06-2019 | Radiotherapy | ASCO 2019 | Article

Researcher comment: Fewer AEs with proton versus photon radiotherapy

Brian Baumann presents their comparative analysis of the adverse event profiles of proton and photon radiotherapy in nonmetastatic patients receiving chemoradiotherapy with curative intent for various solid tumors, including lung cancer (5:28).

13-06-2019 | Screening | ASCO 2019 | Article

Researcher comment: Screening underserved groups with the Lung Bus

Mellisa Wheeler talks about how their mobile low dose-CT lung scanning unit – the Lung Bus – is helping to reach underserved populations in North Carolina, USA. She also comments on the issues of access to care and overscreening, and outlines the next steps (3:54).

04-06-2019 | Non-small cell lung cancer | ASCO 2019 | Article

Expert comment: 5-year update of KEYNOTE-001

ASCO expert David Graham tells us just why he thinks the 5-year survival data from the advanced non-small-cell lung cancer patients enrolled in the phase Ib KEYNOTE-001 trial are so remarkable (1:26).

03-06-2019 | Non-small cell lung cancer | ASCO 2019 | Article

Researcher comment: 5-year KEYNOTE-001 results show long-lasting survival for some advanced NSCLC patients

Edward Garon presents the 5-year follow-up results of the advanced non-small-cell lung cancer cohort of the phase I KEYNOTE-001 trial of pembrolizumab monotherapy (4:12).

01-06-2019 | Lung cancer | ASCO 2019 | Article

Expert highlights: Lung cancer at ASCO 2019

Advisory Board member Ross Camidge comments on his picks for the most exciting lung cancer research being presented at the 2019 ASCO Annual Meeting, including the RELAY trial and the ARROW trial of the RET inhibitor BLU-667 (3:13).

Research news

24-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

Adding chemotherapy to gefitinib improves EGFR-mutated NSCLC outcomes

Supplementing the EGFR–tyrosine kinase inhibitor gefitinib with pemetrexed and carboplatin doubles progression-free survival in patients with advanced, chemotherapy-naïve non-small-cell lung cancer harboring activating EGFR mutations, according to phase III results.

21-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

Neoadjuvant immunotherapy shows promise for resectable NSCLC

Neoadjuvant immunotherapy produces encouraging major pathologic response rates among patients with resectable non-small-cell lung cancer, show data presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

20-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

Maintenance bevacizumab–pemetrexed improves PFS of nonsquamous NSCLC patients

Two studies presented at the 2019 ASCO Annual Meeting show a significant progression-free survival, but not overall survival, benefit with the addition of pemetrexed to bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer.

Image Credits